To evaluate the effect of INCB086550 on PD-L1 internalization, results showed that INCB086550 significantly reduced cell-surface PD-L1.
Cancer Discov. 2022 Jun 2;12(6):1482-1499
CHO PD-L1 cells
13.2 nmol/L (IC50)
1 hour
To evaluate the ability of INCB086550 to block the PD-L1/PD-1 interaction, results showed that INCB086550 effectively blocked PD-L1 binding to PD-1.
Cancer Discov. 2022 Jun 2;12(6):1482-1499
INCB086550 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
4T1-hPD-L1 syngeneic mouse model
Subcutaneous injection
15 mg/kg INCB086550 (twice daily, BID)
INCB086550 treatment for 4 weeks, Deucravacitinib treatment for 2 weeks
To evaluate the antitumor effect of INCB086550 in combination with Deucravacitinib in the 4T1-hPD-L1 model. Results showed that the combination therapy significantly reduced tumor volume and weight, increased the proportion of T cells, B cells, and NK cells, and decreased the proportion of MDSCs.
Anticancer Drugs. 2025 Apr 1;36(4):280-289
Mice
MC38 huPD-L1 tumor model
Oral
2, 20, 200 mg/kg
Twice daily for 14 days
To evaluate the antitumor efficacy of INCB086550 in vivo, results showed that INCB086550 significantly inhibited tumor growth and increased CD8+ T-cell infiltration.
INCB086550 treatment for 4 weeks, Deucravacitinib treatment for 2 weeks
To verify the antitumor efficacy of INCB086550 combined with Deucravacitinib in triple-negative breast cancer models. Results showed that the combination therapy significantly reduced tumor volume and weight, increased the counts of T, B, and natural killer cells, and decreased the proportion of myeloid-derived suppressor cells.
搜索
